chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 79.0
Sex: F
Vaccine: RSV
Symptoms: Diarrhoea, Illness, Loss of personal independence in daily activities
Clinical narrative: significant diarrhea and illness unable to function for several days
Age: 81.0
Sex: M
Vaccine: FLU4
Symptoms: Asthenia, Back pain, Balance disorder, Brain fog, Burning sensation
Clinical narrative: Back pain over kidney area, Sore, almost bloody, gums, Unsteadiness (way increased vertigo), confusion (brain fog), dizziness, drowsiness, mild fever, swollen joints (fingers, knees, ankles [burning sensation] and unusual tiredness and weakness
Age: 81.0
Sex: M
Vaccine: FLU4
Symptoms: Confusional state, Dizziness, Fatigue, Gingival bleeding, Gingival pain
Clinical narrative: Back pain over kidney area, Sore, almost bloody, gums, Unsteadiness (way increased vertigo), confusion (brain fog), dizziness, drowsiness, mild fever, swollen joints (fingers, knees, ankles [burning sensation] and unusual tiredness and weakness
Age: 81.0
Sex: M
Vaccine: FLU4
Symptoms: Joint swelling, Peripheral swelling, Pyrexia, Somnolence, Vertigo
Clinical narrative: Back pain over kidney area, Sore, almost bloody, gums, Unsteadiness (way increased vertigo), confusion (brain fog), dizziness, drowsiness, mild fever, swollen joints (fingers, knees, ankles [burning sensation] and unusual tiredness and weakness
Age: 68.0
Sex: F
Vaccine: VARZOS
Symptoms: Injection site pruritus, Injection site reaction, Injection site swelling, Rash vesicular, Skin exfoliation
Clinical narrative: Injection site swollen, scaly, itchy - 7 months later,  Looks like I got a form of chicken pox on my hands & arm & sometimes neck
Sex: U
Vaccine: COVID19, COVID19
Symptoms: Acupuncture, Asthma, Audiogram normal, Blood pressure abnormal, Blood test abnormal
Clinical narrative: The first and second doses of the COVID-19 Moderna vaccine are more likely than not believed to have caused the below conditions and symptoms.  Few substantial treatments have been prescribed to date given the dearth of clinical providers available to address COVID-19 vaccine injury and the dearth of information to which local clinicians have access.  While the patient has experienced relatively significant improvement compared to her lowest point post-vaccination (thanks to elimination of essentially all life activities, significant rest, acupuncture, traditional medicine herbal supplementation, nattokinase and serrapeptase supplementation, mild physical therapy, etc.), she nowhere near close to her pre-vaccination baselines, cannot work, and cannot complete most IADLs daily or weekly.  Diagnosed Conditions: Aggravation of post-viral myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) (G93.32) (now severe and now meets Consensus Criteria) and development of the following conditions over the span of 24 hours after the first and/or second dose and ~9 months: Mild neurocognitive disorder due to known physiological condition without behavioral disturbance (F06.70); Frontal lobe and executive function deficit (R41.844); Migraine with aura, intractable, with status migrainosus (G43.111); Vestibular migraine; Idiopathic hypersomnia with long sleep time (G47.11); Confusion (R41.0); Postural orthostatic tachycardia syndrome (POTS) (G90.A); Raynaud?s syndrome (I73.0); Unspecified disorder of vestibular function, right ear (H81.91); Nystagmus and other irregular eye movements, left eye (H55); Bilateral temporomandibular joint disorder, unspecified (M26.603); Diarrhea, unspecified (R19.7); Pancreatic steatorrhea (K90.3); Exocrine pancreatic insufficiency (K86. 81) (moderate); Gastro-esophageal reflux disease (GERD) with esophagitis, without bleeding (K21.00);  Chronic superficial gastritis without bleeding (K29.30); Duodenitis without bleeding (K29.80); Acute upper respiratory infection (URI), unspecified (J06. 9); Reactive airway disease (RAD) / Unspecified asthma, uncomplicated (J45.909); Dermatitis, unspecified (L30.9); Gingivitis & pre-periodontal disease (K05)  Symptoms: A long list of symptoms that can be provided separately.
Sex: U
Vaccine: COVID19, COVID19
Symptoms: Bronchial hyperreactivity, Cardiac monitoring abnormal, Cardiac stress test normal, Cerebral disorder, Chest X-ray normal
Clinical narrative: The first and second doses of the COVID-19 Moderna vaccine are more likely than not believed to have caused the below conditions and symptoms.  Few substantial treatments have been prescribed to date given the dearth of clinical providers available to address COVID-19 vaccine injury and the dearth of information to which local clinicians have access.  While the patient has experienced relatively significant improvement compared to her lowest point post-vaccination (thanks to elimination of essentially all life activities, significant rest, acupuncture, traditional medicine herbal supplementation, nattokinase and serrapeptase supplementation, mild physical therapy, etc.), she nowhere near close to her pre-vaccination baselines, cannot work, and cannot complete most IADLs daily or weekly.  Diagnosed Conditions: Aggravation of post-viral myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) (G93.32) (now severe and now meets Consensus Criteria) and development of the following conditions over the span of 24 hours after the first and/or second dose and ~9 months: Mild neurocognitive disorder due to known physiological condition without behavioral disturbance (F06.70); Frontal lobe and executive function deficit (R41.844); Migraine with aura, intractable, with status migrainosus (G43.111); Vestibular migraine; Idiopathic hypersomnia with long sleep time (G47.11); Confusion (R41.0); Postural orthostatic tachycardia syndrome (POTS) (G90.A); Raynaud?s syndrome (I73.0); Unspecified disorder of vestibular function, right ear (H81.91); Nystagmus and other irregular eye movements, left eye (H55); Bilateral temporomandibular joint disorder, unspecified (M26.603); Diarrhea, unspecified (R19.7); Pancreatic steatorrhea (K90.3); Exocrine pancreatic insufficiency (K86. 81) (moderate); Gastro-esophageal reflux disease (GERD) with esophagitis, without bleeding (K21.00);  Chronic superficial gastritis without bleeding (K29.30); Duodenitis without bleeding (K29.80); Acute upper respiratory infection (URI), unspecified (J06. 9); Reactive airway disease (RAD) / Unspecified asthma, uncomplicated (J45.909); Dermatitis, unspecified (L30.9); Gingivitis & pre-periodontal disease (K05)  Symptoms: A long list of symptoms that can be provided separately.
Sex: U
Vaccine: COVID19, COVID19
Symptoms: Chronic fatigue syndrome, Chronic gastritis, Cognitive disorder, Cognitive test, Condition aggravated
Clinical narrative: The first and second doses of the COVID-19 Moderna vaccine are more likely than not believed to have caused the below conditions and symptoms.  Few substantial treatments have been prescribed to date given the dearth of clinical providers available to address COVID-19 vaccine injury and the dearth of information to which local clinicians have access.  While the patient has experienced relatively significant improvement compared to her lowest point post-vaccination (thanks to elimination of essentially all life activities, significant rest, acupuncture, traditional medicine herbal supplementation, nattokinase and serrapeptase supplementation, mild physical therapy, etc.), she nowhere near close to her pre-vaccination baselines, cannot work, and cannot complete most IADLs daily or weekly.  Diagnosed Conditions: Aggravation of post-viral myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) (G93.32) (now severe and now meets Consensus Criteria) and development of the following conditions over the span of 24 hours after the first and/or second dose and ~9 months: Mild neurocognitive disorder due to known physiological condition without behavioral disturbance (F06.70); Frontal lobe and executive function deficit (R41.844); Migraine with aura, intractable, with status migrainosus (G43.111); Vestibular migraine; Idiopathic hypersomnia with long sleep time (G47.11); Confusion (R41.0); Postural orthostatic tachycardia syndrome (POTS) (G90.A); Raynaud?s syndrome (I73.0); Unspecified disorder of vestibular function, right ear (H81.91); Nystagmus and other irregular eye movements, left eye (H55); Bilateral temporomandibular joint disorder, unspecified (M26.603); Diarrhea, unspecified (R19.7); Pancreatic steatorrhea (K90.3); Exocrine pancreatic insufficiency (K86. 81) (moderate); Gastro-esophageal reflux disease (GERD) with esophagitis, without bleeding (K21.00);  Chronic superficial gastritis without bleeding (K29.30); Duodenitis without bleeding (K29.80); Acute upper respiratory infection (URI), unspecified (J06. 9); Reactive airway disease (RAD) / Unspecified asthma, uncomplicated (J45.909); Dermatitis, unspecified (L30.9); Gingivitis & pre-periodontal disease (K05)  Symptoms: A long list of symptoms that can be provided separately.
Sex: U
Vaccine: COVID19, COVID19
Symptoms: Confusional state, Dermatitis, Diarrhoea, Duodenitis, Echocardiogram
Clinical narrative: The first and second doses of the COVID-19 Moderna vaccine are more likely than not believed to have caused the below conditions and symptoms.  Few substantial treatments have been prescribed to date given the dearth of clinical providers available to address COVID-19 vaccine injury and the dearth of information to which local clinicians have access.  While the patient has experienced relatively significant improvement compared to her lowest point post-vaccination (thanks to elimination of essentially all life activities, significant rest, acupuncture, traditional medicine herbal supplementation, nattokinase and serrapeptase supplementation, mild physical therapy, etc.), she nowhere near close to her pre-vaccination baselines, cannot work, and cannot complete most IADLs daily or weekly.  Diagnosed Conditions: Aggravation of post-viral myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) (G93.32) (now severe and now meets Consensus Criteria) and development of the following conditions over the span of 24 hours after the first and/or second dose and ~9 months: Mild neurocognitive disorder due to known physiological condition without behavioral disturbance (F06.70); Frontal lobe and executive function deficit (R41.844); Migraine with aura, intractable, with status migrainosus (G43.111); Vestibular migraine; Idiopathic hypersomnia with long sleep time (G47.11); Confusion (R41.0); Postural orthostatic tachycardia syndrome (POTS) (G90.A); Raynaud?s syndrome (I73.0); Unspecified disorder of vestibular function, right ear (H81.91); Nystagmus and other irregular eye movements, left eye (H55); Bilateral temporomandibular joint disorder, unspecified (M26.603); Diarrhea, unspecified (R19.7); Pancreatic steatorrhea (K90.3); Exocrine pancreatic insufficiency (K86. 81) (moderate); Gastro-esophageal reflux disease (GERD) with esophagitis, without bleeding (K21.00);  Chronic superficial gastritis without bleeding (K29.30); Duodenitis without bleeding (K29.80); Acute upper respiratory infection (URI), unspecified (J06. 9); Reactive airway disease (RAD) / Unspecified asthma, uncomplicated (J45.909); Dermatitis, unspecified (L30.9); Gingivitis & pre-periodontal disease (K05)  Symptoms: A long list of symptoms that can be provided separately.
Sex: U
Vaccine: COVID19, COVID19
Symptoms: Electrocardiogram ambulatory normal, Electrocardiogram normal, Electronystagmogram, Endoscopy upper gastrointestinal tract abnormal, Executive dysfunction
Clinical narrative: The first and second doses of the COVID-19 Moderna vaccine are more likely than not believed to have caused the below conditions and symptoms.  Few substantial treatments have been prescribed to date given the dearth of clinical providers available to address COVID-19 vaccine injury and the dearth of information to which local clinicians have access.  While the patient has experienced relatively significant improvement compared to her lowest point post-vaccination (thanks to elimination of essentially all life activities, significant rest, acupuncture, traditional medicine herbal supplementation, nattokinase and serrapeptase supplementation, mild physical therapy, etc.), she nowhere near close to her pre-vaccination baselines, cannot work, and cannot complete most IADLs daily or weekly.  Diagnosed Conditions: Aggravation of post-viral myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) (G93.32) (now severe and now meets Consensus Criteria) and development of the following conditions over the span of 24 hours after the first and/or second dose and ~9 months: Mild neurocognitive disorder due to known physiological condition without behavioral disturbance (F06.70); Frontal lobe and executive function deficit (R41.844); Migraine with aura, intractable, with status migrainosus (G43.111); Vestibular migraine; Idiopathic hypersomnia with long sleep time (G47.11); Confusion (R41.0); Postural orthostatic tachycardia syndrome (POTS) (G90.A); Raynaud?s syndrome (I73.0); Unspecified disorder of vestibular function, right ear (H81.91); Nystagmus and other irregular eye movements, left eye (H55); Bilateral temporomandibular joint disorder, unspecified (M26.603); Diarrhea, unspecified (R19.7); Pancreatic steatorrhea (K90.3); Exocrine pancreatic insufficiency (K86. 81) (moderate); Gastro-esophageal reflux disease (GERD) with esophagitis, without bleeding (K21.00);  Chronic superficial gastritis without bleeding (K29.30); Duodenitis without bleeding (K29.80); Acute upper respiratory infection (URI), unspecified (J06. 9); Reactive airway disease (RAD) / Unspecified asthma, uncomplicated (J45.909); Dermatitis, unspecified (L30.9); Gingivitis & pre-periodontal disease (K05)  Symptoms: A long list of symptoms that can be provided separately.
Sex: U
Vaccine: COVID19, COVID19
Symptoms: Eye movement disorder, Faecal elastase test, Gastrointestinal tract biopsy, Gastrooesophageal reflux disease, Gingivitis
Clinical narrative: The first and second doses of the COVID-19 Moderna vaccine are more likely than not believed to have caused the below conditions and symptoms.  Few substantial treatments have been prescribed to date given the dearth of clinical providers available to address COVID-19 vaccine injury and the dearth of information to which local clinicians have access.  While the patient has experienced relatively significant improvement compared to her lowest point post-vaccination (thanks to elimination of essentially all life activities, significant rest, acupuncture, traditional medicine herbal supplementation, nattokinase and serrapeptase supplementation, mild physical therapy, etc.), she nowhere near close to her pre-vaccination baselines, cannot work, and cannot complete most IADLs daily or weekly.  Diagnosed Conditions: Aggravation of post-viral myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) (G93.32) (now severe and now meets Consensus Criteria) and development of the following conditions over the span of 24 hours after the first and/or second dose and ~9 months: Mild neurocognitive disorder due to known physiological condition without behavioral disturbance (F06.70); Frontal lobe and executive function deficit (R41.844); Migraine with aura, intractable, with status migrainosus (G43.111); Vestibular migraine; Idiopathic hypersomnia with long sleep time (G47.11); Confusion (R41.0); Postural orthostatic tachycardia syndrome (POTS) (G90.A); Raynaud?s syndrome (I73.0); Unspecified disorder of vestibular function, right ear (H81.91); Nystagmus and other irregular eye movements, left eye (H55); Bilateral temporomandibular joint disorder, unspecified (M26.603); Diarrhea, unspecified (R19.7); Pancreatic steatorrhea (K90.3); Exocrine pancreatic insufficiency (K86. 81) (moderate); Gastro-esophageal reflux disease (GERD) with esophagitis, without bleeding (K21.00);  Chronic superficial gastritis without bleeding (K29.30); Duodenitis without bleeding (K29.80); Acute upper respiratory infection (URI), unspecified (J06. 9); Reactive airway disease (RAD) / Unspecified asthma, uncomplicated (J45.909); Dermatitis, unspecified (L30.9); Gingivitis & pre-periodontal disease (K05)  Symptoms: A long list of symptoms that can be provided separately.
Sex: U
Vaccine: COVID19, COVID19
Symptoms: Hypersomnia, Impaired work ability, Loss of personal independence in daily activities, Magnetic resonance cholangiopancreatography, Magnetic resonance imaging abdominal
Clinical narrative: The first and second doses of the COVID-19 Moderna vaccine are more likely than not believed to have caused the below conditions and symptoms.  Few substantial treatments have been prescribed to date given the dearth of clinical providers available to address COVID-19 vaccine injury and the dearth of information to which local clinicians have access.  While the patient has experienced relatively significant improvement compared to her lowest point post-vaccination (thanks to elimination of essentially all life activities, significant rest, acupuncture, traditional medicine herbal supplementation, nattokinase and serrapeptase supplementation, mild physical therapy, etc.), she nowhere near close to her pre-vaccination baselines, cannot work, and cannot complete most IADLs daily or weekly.  Diagnosed Conditions: Aggravation of post-viral myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) (G93.32) (now severe and now meets Consensus Criteria) and development of the following conditions over the span of 24 hours after the first and/or second dose and ~9 months: Mild neurocognitive disorder due to known physiological condition without behavioral disturbance (F06.70); Frontal lobe and executive function deficit (R41.844); Migraine with aura, intractable, with status migrainosus (G43.111); Vestibular migraine; Idiopathic hypersomnia with long sleep time (G47.11); Confusion (R41.0); Postural orthostatic tachycardia syndrome (POTS) (G90.A); Raynaud?s syndrome (I73.0); Unspecified disorder of vestibular function, right ear (H81.91); Nystagmus and other irregular eye movements, left eye (H55); Bilateral temporomandibular joint disorder, unspecified (M26.603); Diarrhea, unspecified (R19.7); Pancreatic steatorrhea (K90.3); Exocrine pancreatic insufficiency (K86. 81) (moderate); Gastro-esophageal reflux disease (GERD) with esophagitis, without bleeding (K21.00);  Chronic superficial gastritis without bleeding (K29.30); Duodenitis without bleeding (K29.80); Acute upper respiratory infection (URI), unspecified (J06. 9); Reactive airway disease (RAD) / Unspecified asthma, uncomplicated (J45.909); Dermatitis, unspecified (L30.9); Gingivitis & pre-periodontal disease (K05)  Symptoms: A long list of symptoms that can be provided separately.
Sex: U
Vaccine: COVID19, COVID19
Symptoms: Magnetic resonance imaging abdominal normal, Magnetic resonance imaging head normal, Magnetic resonance imaging pelvic, Magnetic resonance imaging spinal normal, Migraine with aura
Clinical narrative: The first and second doses of the COVID-19 Moderna vaccine are more likely than not believed to have caused the below conditions and symptoms.  Few substantial treatments have been prescribed to date given the dearth of clinical providers available to address COVID-19 vaccine injury and the dearth of information to which local clinicians have access.  While the patient has experienced relatively significant improvement compared to her lowest point post-vaccination (thanks to elimination of essentially all life activities, significant rest, acupuncture, traditional medicine herbal supplementation, nattokinase and serrapeptase supplementation, mild physical therapy, etc.), she nowhere near close to her pre-vaccination baselines, cannot work, and cannot complete most IADLs daily or weekly.  Diagnosed Conditions: Aggravation of post-viral myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) (G93.32) (now severe and now meets Consensus Criteria) and development of the following conditions over the span of 24 hours after the first and/or second dose and ~9 months: Mild neurocognitive disorder due to known physiological condition without behavioral disturbance (F06.70); Frontal lobe and executive function deficit (R41.844); Migraine with aura, intractable, with status migrainosus (G43.111); Vestibular migraine; Idiopathic hypersomnia with long sleep time (G47.11); Confusion (R41.0); Postural orthostatic tachycardia syndrome (POTS) (G90.A); Raynaud?s syndrome (I73.0); Unspecified disorder of vestibular function, right ear (H81.91); Nystagmus and other irregular eye movements, left eye (H55); Bilateral temporomandibular joint disorder, unspecified (M26.603); Diarrhea, unspecified (R19.7); Pancreatic steatorrhea (K90.3); Exocrine pancreatic insufficiency (K86. 81) (moderate); Gastro-esophageal reflux disease (GERD) with esophagitis, without bleeding (K21.00);  Chronic superficial gastritis without bleeding (K29.30); Duodenitis without bleeding (K29.80); Acute upper respiratory infection (URI), unspecified (J06. 9); Reactive airway disease (RAD) / Unspecified asthma, uncomplicated (J45.909); Dermatitis, unspecified (L30.9); Gingivitis & pre-periodontal disease (K05)  Symptoms: A long list of symptoms that can be provided separately.
Sex: U
Vaccine: COVID19, COVID19
Symptoms: Neuropsychological test abnormal, Nystagmus, Oesophagitis, Oesophagogastroduodenoscopy abnormal, Pancreatic failure
Clinical narrative: The first and second doses of the COVID-19 Moderna vaccine are more likely than not believed to have caused the below conditions and symptoms.  Few substantial treatments have been prescribed to date given the dearth of clinical providers available to address COVID-19 vaccine injury and the dearth of information to which local clinicians have access.  While the patient has experienced relatively significant improvement compared to her lowest point post-vaccination (thanks to elimination of essentially all life activities, significant rest, acupuncture, traditional medicine herbal supplementation, nattokinase and serrapeptase supplementation, mild physical therapy, etc.), she nowhere near close to her pre-vaccination baselines, cannot work, and cannot complete most IADLs daily or weekly.  Diagnosed Conditions: Aggravation of post-viral myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) (G93.32) (now severe and now meets Consensus Criteria) and development of the following conditions over the span of 24 hours after the first and/or second dose and ~9 months: Mild neurocognitive disorder due to known physiological condition without behavioral disturbance (F06.70); Frontal lobe and executive function deficit (R41.844); Migraine with aura, intractable, with status migrainosus (G43.111); Vestibular migraine; Idiopathic hypersomnia with long sleep time (G47.11); Confusion (R41.0); Postural orthostatic tachycardia syndrome (POTS) (G90.A); Raynaud?s syndrome (I73.0); Unspecified disorder of vestibular function, right ear (H81.91); Nystagmus and other irregular eye movements, left eye (H55); Bilateral temporomandibular joint disorder, unspecified (M26.603); Diarrhea, unspecified (R19.7); Pancreatic steatorrhea (K90.3); Exocrine pancreatic insufficiency (K86. 81) (moderate); Gastro-esophageal reflux disease (GERD) with esophagitis, without bleeding (K21.00);  Chronic superficial gastritis without bleeding (K29.30); Duodenitis without bleeding (K29.80); Acute upper respiratory infection (URI), unspecified (J06. 9); Reactive airway disease (RAD) / Unspecified asthma, uncomplicated (J45.909); Dermatitis, unspecified (L30.9); Gingivitis & pre-periodontal disease (K05)  Symptoms: A long list of symptoms that can be provided separately.
Sex: U
Vaccine: COVID19, COVID19
Symptoms: Periodontal disease, Postural orthostatic tachycardia syndrome, Pulmonary function test abnormal, Raynaud's phenomenon, Scan with contrast normal
Clinical narrative: The first and second doses of the COVID-19 Moderna vaccine are more likely than not believed to have caused the below conditions and symptoms.  Few substantial treatments have been prescribed to date given the dearth of clinical providers available to address COVID-19 vaccine injury and the dearth of information to which local clinicians have access.  While the patient has experienced relatively significant improvement compared to her lowest point post-vaccination (thanks to elimination of essentially all life activities, significant rest, acupuncture, traditional medicine herbal supplementation, nattokinase and serrapeptase supplementation, mild physical therapy, etc.), she nowhere near close to her pre-vaccination baselines, cannot work, and cannot complete most IADLs daily or weekly.  Diagnosed Conditions: Aggravation of post-viral myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) (G93.32) (now severe and now meets Consensus Criteria) and development of the following conditions over the span of 24 hours after the first and/or second dose and ~9 months: Mild neurocognitive disorder due to known physiological condition without behavioral disturbance (F06.70); Frontal lobe and executive function deficit (R41.844); Migraine with aura, intractable, with status migrainosus (G43.111); Vestibular migraine; Idiopathic hypersomnia with long sleep time (G47.11); Confusion (R41.0); Postural orthostatic tachycardia syndrome (POTS) (G90.A); Raynaud?s syndrome (I73.0); Unspecified disorder of vestibular function, right ear (H81.91); Nystagmus and other irregular eye movements, left eye (H55); Bilateral temporomandibular joint disorder, unspecified (M26.603); Diarrhea, unspecified (R19.7); Pancreatic steatorrhea (K90.3); Exocrine pancreatic insufficiency (K86. 81) (moderate); Gastro-esophageal reflux disease (GERD) with esophagitis, without bleeding (K21.00);  Chronic superficial gastritis without bleeding (K29.30); Duodenitis without bleeding (K29.80); Acute upper respiratory infection (URI), unspecified (J06. 9); Reactive airway disease (RAD) / Unspecified asthma, uncomplicated (J45.909); Dermatitis, unspecified (L30.9); Gingivitis & pre-periodontal disease (K05)  Symptoms: A long list of symptoms that can be provided separately.
Sex: U
Vaccine: COVID19, COVID19
Symptoms: Sleep study, Sleep study normal, Spinal X-ray normal, Status migrainosus, Steatorrhoea
Clinical narrative: The first and second doses of the COVID-19 Moderna vaccine are more likely than not believed to have caused the below conditions and symptoms.  Few substantial treatments have been prescribed to date given the dearth of clinical providers available to address COVID-19 vaccine injury and the dearth of information to which local clinicians have access.  While the patient has experienced relatively significant improvement compared to her lowest point post-vaccination (thanks to elimination of essentially all life activities, significant rest, acupuncture, traditional medicine herbal supplementation, nattokinase and serrapeptase supplementation, mild physical therapy, etc.), she nowhere near close to her pre-vaccination baselines, cannot work, and cannot complete most IADLs daily or weekly.  Diagnosed Conditions: Aggravation of post-viral myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) (G93.32) (now severe and now meets Consensus Criteria) and development of the following conditions over the span of 24 hours after the first and/or second dose and ~9 months: Mild neurocognitive disorder due to known physiological condition without behavioral disturbance (F06.70); Frontal lobe and executive function deficit (R41.844); Migraine with aura, intractable, with status migrainosus (G43.111); Vestibular migraine; Idiopathic hypersomnia with long sleep time (G47.11); Confusion (R41.0); Postural orthostatic tachycardia syndrome (POTS) (G90.A); Raynaud?s syndrome (I73.0); Unspecified disorder of vestibular function, right ear (H81.91); Nystagmus and other irregular eye movements, left eye (H55); Bilateral temporomandibular joint disorder, unspecified (M26.603); Diarrhea, unspecified (R19.7); Pancreatic steatorrhea (K90.3); Exocrine pancreatic insufficiency (K86. 81) (moderate); Gastro-esophageal reflux disease (GERD) with esophagitis, without bleeding (K21.00);  Chronic superficial gastritis without bleeding (K29.30); Duodenitis without bleeding (K29.80); Acute upper respiratory infection (URI), unspecified (J06. 9); Reactive airway disease (RAD) / Unspecified asthma, uncomplicated (J45.909); Dermatitis, unspecified (L30.9); Gingivitis & pre-periodontal disease (K05)  Symptoms: A long list of symptoms that can be provided separately.
Sex: U
Vaccine: COVID19, COVID19
Symptoms: Temporomandibular joint syndrome, Tilt table test normal, Tympanometry normal, Ultrasound Doppler normal, Ultrasound abdomen normal
Clinical narrative: The first and second doses of the COVID-19 Moderna vaccine are more likely than not believed to have caused the below conditions and symptoms.  Few substantial treatments have been prescribed to date given the dearth of clinical providers available to address COVID-19 vaccine injury and the dearth of information to which local clinicians have access.  While the patient has experienced relatively significant improvement compared to her lowest point post-vaccination (thanks to elimination of essentially all life activities, significant rest, acupuncture, traditional medicine herbal supplementation, nattokinase and serrapeptase supplementation, mild physical therapy, etc.), she nowhere near close to her pre-vaccination baselines, cannot work, and cannot complete most IADLs daily or weekly.  Diagnosed Conditions: Aggravation of post-viral myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) (G93.32) (now severe and now meets Consensus Criteria) and development of the following conditions over the span of 24 hours after the first and/or second dose and ~9 months: Mild neurocognitive disorder due to known physiological condition without behavioral disturbance (F06.70); Frontal lobe and executive function deficit (R41.844); Migraine with aura, intractable, with status migrainosus (G43.111); Vestibular migraine; Idiopathic hypersomnia with long sleep time (G47.11); Confusion (R41.0); Postural orthostatic tachycardia syndrome (POTS) (G90.A); Raynaud?s syndrome (I73.0); Unspecified disorder of vestibular function, right ear (H81.91); Nystagmus and other irregular eye movements, left eye (H55); Bilateral temporomandibular joint disorder, unspecified (M26.603); Diarrhea, unspecified (R19.7); Pancreatic steatorrhea (K90.3); Exocrine pancreatic insufficiency (K86. 81) (moderate); Gastro-esophageal reflux disease (GERD) with esophagitis, without bleeding (K21.00);  Chronic superficial gastritis without bleeding (K29.30); Duodenitis without bleeding (K29.80); Acute upper respiratory infection (URI), unspecified (J06. 9); Reactive airway disease (RAD) / Unspecified asthma, uncomplicated (J45.909); Dermatitis, unspecified (L30.9); Gingivitis & pre-periodontal disease (K05)  Symptoms: A long list of symptoms that can be provided separately.
Sex: U
Vaccine: COVID19, COVID19
Symptoms: Upper respiratory tract infection, Urine analysis normal, Vestibular disorder, Vestibular migraine
Clinical narrative: The first and second doses of the COVID-19 Moderna vaccine are more likely than not believed to have caused the below conditions and symptoms.  Few substantial treatments have been prescribed to date given the dearth of clinical providers available to address COVID-19 vaccine injury and the dearth of information to which local clinicians have access.  While the patient has experienced relatively significant improvement compared to her lowest point post-vaccination (thanks to elimination of essentially all life activities, significant rest, acupuncture, traditional medicine herbal supplementation, nattokinase and serrapeptase supplementation, mild physical therapy, etc.), she nowhere near close to her pre-vaccination baselines, cannot work, and cannot complete most IADLs daily or weekly.  Diagnosed Conditions: Aggravation of post-viral myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) (G93.32) (now severe and now meets Consensus Criteria) and development of the following conditions over the span of 24 hours after the first and/or second dose and ~9 months: Mild neurocognitive disorder due to known physiological condition without behavioral disturbance (F06.70); Frontal lobe and executive function deficit (R41.844); Migraine with aura, intractable, with status migrainosus (G43.111); Vestibular migraine; Idiopathic hypersomnia with long sleep time (G47.11); Confusion (R41.0); Postural orthostatic tachycardia syndrome (POTS) (G90.A); Raynaud?s syndrome (I73.0); Unspecified disorder of vestibular function, right ear (H81.91); Nystagmus and other irregular eye movements, left eye (H55); Bilateral temporomandibular joint disorder, unspecified (M26.603); Diarrhea, unspecified (R19.7); Pancreatic steatorrhea (K90.3); Exocrine pancreatic insufficiency (K86. 81) (moderate); Gastro-esophageal reflux disease (GERD) with esophagitis, without bleeding (K21.00);  Chronic superficial gastritis without bleeding (K29.30); Duodenitis without bleeding (K29.80); Acute upper respiratory infection (URI), unspecified (J06. 9); Reactive airway disease (RAD) / Unspecified asthma, uncomplicated (J45.909); Dermatitis, unspecified (L30.9); Gingivitis & pre-periodontal disease (K05)  Symptoms: A long list of symptoms that can be provided separately.
Age: 40.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Alanine aminotransferase increased, Aspartate aminotransferase increased, Biopsy liver abnormal, Computerised tomogram normal, Cyanosis
Clinical narrative: Routine bloodwork for annual physical showed acute liver injury with extremely elevated AST (412) and ALT (1323) without accompanying jaundice. Referral to a gastroenterologist for follow up also showed antibodies for Epstein-Barr despite no history of infection during lifetime. Liver biopsy showed level 1 scarring with no indication of cirrhosis. Potential diagnosis of systematic lupus with a prescribed course of 40mg/day of prednisone before referral to a specialist. In early 2023 hepatologist diagnosed autoimmune hepatitis and continued course of prednisone while adding 50mg/day of azathioprene. Improvement in ALT/AST levels over the following year resulted in gradual scaling down of prednisone to 10mg/day and scaling up of azathioprene to 200mg/day, which continues presently. In December of 2023, patient noted gradual swelling of right arm in annual physical, with the appearance of a varicose vein cluster on right bicep. Patient was referred for DVT sonogram imaging which showed no presence of DVT. 24 hours later patient self-admitted to emergency room with dramatic swelling in right arm along with arm turning blue. CT scan revealed no apparent nerve, vein, or arterial compression present. An additional sonogram noted several clots in right underarm and clavicle area. Patient was admitted to hospital overnight and prescribed a course of intravenous Lovenox at night and the following morning, before being discharged with a course of apixaban.
Age: 40.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Epstein-Barr virus antibody positive, Liver disorder, Liver injury, Peripheral swelling, Thrombosis
Clinical narrative: Routine bloodwork for annual physical showed acute liver injury with extremely elevated AST (412) and ALT (1323) without accompanying jaundice. Referral to a gastroenterologist for follow up also showed antibodies for Epstein-Barr despite no history of infection during lifetime. Liver biopsy showed level 1 scarring with no indication of cirrhosis. Potential diagnosis of systematic lupus with a prescribed course of 40mg/day of prednisone before referral to a specialist. In early 2023 hepatologist diagnosed autoimmune hepatitis and continued course of prednisone while adding 50mg/day of azathioprene. Improvement in ALT/AST levels over the following year resulted in gradual scaling down of prednisone to 10mg/day and scaling up of azathioprene to 200mg/day, which continues presently. In December of 2023, patient noted gradual swelling of right arm in annual physical, with the appearance of a varicose vein cluster on right bicep. Patient was referred for DVT sonogram imaging which showed no presence of DVT. 24 hours later patient self-admitted to emergency room with dramatic swelling in right arm along with arm turning blue. CT scan revealed no apparent nerve, vein, or arterial compression present. An additional sonogram noted several clots in right underarm and clavicle area. Patient was admitted to hospital overnight and prescribed a course of intravenous Lovenox at night and the following morning, before being discharged with a course of apixaban.
Age: 40.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Ultrasound Doppler normal, Ultrasound scan abnormal, Varicose vein
Clinical narrative: Routine bloodwork for annual physical showed acute liver injury with extremely elevated AST (412) and ALT (1323) without accompanying jaundice. Referral to a gastroenterologist for follow up also showed antibodies for Epstein-Barr despite no history of infection during lifetime. Liver biopsy showed level 1 scarring with no indication of cirrhosis. Potential diagnosis of systematic lupus with a prescribed course of 40mg/day of prednisone before referral to a specialist. In early 2023 hepatologist diagnosed autoimmune hepatitis and continued course of prednisone while adding 50mg/day of azathioprene. Improvement in ALT/AST levels over the following year resulted in gradual scaling down of prednisone to 10mg/day and scaling up of azathioprene to 200mg/day, which continues presently. In December of 2023, patient noted gradual swelling of right arm in annual physical, with the appearance of a varicose vein cluster on right bicep. Patient was referred for DVT sonogram imaging which showed no presence of DVT. 24 hours later patient self-admitted to emergency room with dramatic swelling in right arm along with arm turning blue. CT scan revealed no apparent nerve, vein, or arterial compression present. An additional sonogram noted several clots in right underarm and clavicle area. Patient was admitted to hospital overnight and prescribed a course of intravenous Lovenox at night and the following morning, before being discharged with a course of apixaban.
Age: 22.0
Sex: F
Vaccine: FLU4
Symptoms: Chest X-ray, Dyspnoea, Hemiparesis, Laboratory test, Magnetic resonance imaging head
Clinical narrative: Weakness and tingling on the right side of her body body arms and legs with burning pain in neck, which then moved to the left side of her body and creating episodes of exertional syncope. Also having trouble breathing.
Age: 22.0
Sex: F
Vaccine: FLU4
Symptoms: Magnetic resonance imaging spinal, Neck pain, Nerve conduction studies, Pain, Pain in extremity
Clinical narrative: Weakness and tingling on the right side of her body body arms and legs with burning pain in neck, which then moved to the left side of her body and creating episodes of exertional syncope. Also having trouble breathing.
Age: 22.0
Sex: F
Vaccine: FLU4
Symptoms: Paraesthesia, Pulmonary function test, Spinal X-ray, Syncope
Clinical narrative: Weakness and tingling on the right side of her body body arms and legs with burning pain in neck, which then moved to the left side of her body and creating episodes of exertional syncope. Also having trouble breathing.
Age: 63.0
Sex: F
Vaccine: RSV
Symptoms: Autonomic nervous system imbalance, Balance disorder, Blood pressure fluctuation, Endotracheal intubation, Gastrostomy
Clinical narrative: The patient developed Guillain -Barre syndrome, which eventually led to almost complete quadriplegia, respiratory failure requiring intubation and mechanical ventillation. Her first symptoms started 7 days after the vaccination with bilateral hand and feet numbness and some balance problems. Admitted to the hospital 2 days after the onset of symptoms, and 36 hours after admission started developing weakness in lower extremities, which progressed within 48-72 hours to severe weakness of both upper and lower extremities. She also developed sever autonomic instability with blood pressure variation from 70 mm HG to 160 mm Hg.  Respiratory failure developed about 72 hours after onset of muscle weakness. She was intubated and tracheostomy and PEG tube were placed on 7 th day of intubation.  Received 5 days of IVIG therapy with the first dose on 3rd day of hospitalization. Transferred to tertiary facility after 20 days of hospitalization.
Age: 63.0
Sex: F
Vaccine: RSV
Symptoms: Guillain-Barre syndrome, Hypoaesthesia, Immunoglobulin therapy, Mechanical ventilation, Muscular weakness
Clinical narrative: The patient developed Guillain -Barre syndrome, which eventually led to almost complete quadriplegia, respiratory failure requiring intubation and mechanical ventillation. Her first symptoms started 7 days after the vaccination with bilateral hand and feet numbness and some balance problems. Admitted to the hospital 2 days after the onset of symptoms, and 36 hours after admission started developing weakness in lower extremities, which progressed within 48-72 hours to severe weakness of both upper and lower extremities. She also developed sever autonomic instability with blood pressure variation from 70 mm HG to 160 mm Hg.  Respiratory failure developed about 72 hours after onset of muscle weakness. She was intubated and tracheostomy and PEG tube were placed on 7 th day of intubation.  Received 5 days of IVIG therapy with the first dose on 3rd day of hospitalization. Transferred to tertiary facility after 20 days of hospitalization.
Age: 63.0
Sex: F
Vaccine: RSV
Symptoms: Quadriplegia, Respiratory failure, Tracheostomy
Clinical narrative: The patient developed Guillain -Barre syndrome, which eventually led to almost complete quadriplegia, respiratory failure requiring intubation and mechanical ventillation. Her first symptoms started 7 days after the vaccination with bilateral hand and feet numbness and some balance problems. Admitted to the hospital 2 days after the onset of symptoms, and 36 hours after admission started developing weakness in lower extremities, which progressed within 48-72 hours to severe weakness of both upper and lower extremities. She also developed sever autonomic instability with blood pressure variation from 70 mm HG to 160 mm Hg.  Respiratory failure developed about 72 hours after onset of muscle weakness. She was intubated and tracheostomy and PEG tube were placed on 7 th day of intubation.  Received 5 days of IVIG therapy with the first dose on 3rd day of hospitalization. Transferred to tertiary facility after 20 days of hospitalization.
Age: 72.0
Sex: F
Vaccine: UNK
Symptoms: Arthralgia, Chills, Neck pain, Pain in extremity, Pyrexia
Clinical narrative: Sore arm, shoulder & neck.  Fever and violent chills from 9 pm till about 11 pm
Age: 70.0
Sex: F
Vaccine: VARZOS
Symptoms: Abdominal pain, Anion gap, Blood calcium, Blood chloride, Blood creatinine
Clinical narrative: Left flank pain began 11/15/23 feeling as intermittent muscle cramp.  Late that evening I experienced excruciating sharp stabbing pains at frequent intervals which did not respond to heat, Tylenol, changing positions.   Pain persisted through the night to 11/16/23 so I went to emergency department at approx.  6:30 AM.
Age: 70.0
Sex: F
Vaccine: VARZOS
Symptoms: Blood glucose, Blood potassium, Blood sodium, Blood urea, Carbon dioxide
Clinical narrative: Left flank pain began 11/15/23 feeling as intermittent muscle cramp.  Late that evening I experienced excruciating sharp stabbing pains at frequent intervals which did not respond to heat, Tylenol, changing positions.   Pain persisted through the night to 11/16/23 so I went to emergency department at approx.  6:30 AM.
Age: 70.0
Sex: F
Vaccine: VARZOS
Symptoms: Computerised tomogram abdomen abnormal, Flank pain, Glomerular filtration rate decreased, Muscle spasms, Nephrolithiasis
Clinical narrative: Left flank pain began 11/15/23 feeling as intermittent muscle cramp.  Late that evening I experienced excruciating sharp stabbing pains at frequent intervals which did not respond to heat, Tylenol, changing positions.   Pain persisted through the night to 11/16/23 so I went to emergency department at approx.  6:30 AM.
Age: 55.0
Sex: F
Vaccine: VARZOS
Symptoms: Chills, Fatigue, Injection site erythema, Injection site pain, Pyrexia
Clinical narrative: Pt reports NDC 58160082311; RX:. 1 day post vaccine administration, 102° fever for several hours, chills, fatigue. 2 days post vaccination, fever, chills and fatigue resolved. Has redness and pain surrounding injection site
Age: 23.0
Sex: F
Vaccine: COVID19-2
Symptoms: Abortion spontaneous, Exposure during pregnancy, Human chorionic gonadotropin, Hypoaesthesia, Magnetic resonance imaging
Clinical narrative: I had a spontaneous abortion 19th of November 2022. I had 1 month and 2 weeks of pregnancy. Estimated due date was in July 2023. Also on February 1, 2023 I had numbness on the R side of arm/foot. I was hospitalized on February 4 & was diagnosed with Multiple Sclerosis.
Age: 23.0
Sex: F
Vaccine: COVID19-2
Symptoms: Multiple sclerosis, Ultrasound scan
Clinical narrative: I had a spontaneous abortion 19th of November 2022. I had 1 month and 2 weeks of pregnancy. Estimated due date was in July 2023. Also on February 1, 2023 I had numbness on the R side of arm/foot. I was hospitalized on February 4 & was diagnosed with Multiple Sclerosis.
Age: 65.0
Sex: F
Vaccine: RSV
Symptoms: Erythema, Induration, Pruritus
Clinical narrative: Redness, itching, skin seemed hardened in affected area. Lasted 3-4 days. Benadryl helped with itching until it cleared up.
Age: 52.0
Sex: M
Vaccine: VARZOS
Symptoms: Chest pain, Dizziness, Fatigue, Myalgia
Clinical narrative: Tiredness, sore muscles, mild chest pain, and dizziness.
Age: 41.0
Sex: F
Vaccine: MMR, UNK
Symptoms: Eye pain, Fatigue, Lymph node pain, Lymphadenopathy, Myalgia
Clinical narrative: The first reaction was within two weeks after the injection, and consisted of several painful swollen lymph nodes on my neck, generalized whole-body skin tenderness, whole body muscle soreness, low grade fever, ever so slight post nasal drip, and major fatigue, with pain in moving neck and eyes. This lasted two days, except for the lymph swelling, which lasted about a week.  Messaged my doctor regarding this and stayed home from work because of pain and fatigue.
Age: 41.0
Sex: F
Vaccine: MMR, UNK
Symptoms: Neck pain, Pain, Pain of skin, Pyrexia, Upper-airway cough syndrome
Clinical narrative: The first reaction was within two weeks after the injection, and consisted of several painful swollen lymph nodes on my neck, generalized whole-body skin tenderness, whole body muscle soreness, low grade fever, ever so slight post nasal drip, and major fatigue, with pain in moving neck and eyes. This lasted two days, except for the lymph swelling, which lasted about a week.  Messaged my doctor regarding this and stayed home from work because of pain and fatigue.
Age: 37.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Amino acid level, Angiocardiogram, Anti-cyclic citrullinated peptide antibody, Anti-ganglioside antibody, Antinuclear antibody
Clinical narrative: Near syncope, loss of balance, palpitations, weakness, SOB that began after the 1st dose and before the 2nd dose, however the symptoms worsened following the 2nd dose and persisted into the next year until present.
Age: 37.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Asthenia, Balance disorder, Biopsy skin, Blood copper, Blood creatine phosphokinase
Clinical narrative: Near syncope, loss of balance, palpitations, weakness, SOB that began after the 1st dose and before the 2nd dose, however the symptoms worsened following the 2nd dose and persisted into the next year until present.
Age: 37.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Blood folate, Blood magnesium, Blood parathyroid hormone, Blood phosphorus, Blood thyroid stimulating hormone
Clinical narrative: Near syncope, loss of balance, palpitations, weakness, SOB that began after the 1st dose and before the 2nd dose, however the symptoms worsened following the 2nd dose and persisted into the next year until present.
Age: 37.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Blood zinc, Borrelia test, C-reactive protein, Cardiac monitoring, Chest X-ray
Clinical narrative: Near syncope, loss of balance, palpitations, weakness, SOB that began after the 1st dose and before the 2nd dose, however the symptoms worsened following the 2nd dose and persisted into the next year until present.